Citations

Showing 10 of 108094 citations.

Editorial: paternal use of IBD therapies and risk of infant infection
Kane, Sunanda V. , Kane, S

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 8, 2022 | Volume: 56 | Issue: 5 | Pages: 902-902

10.1111/apt.17150 | PMID 35934849 Get It

LINKED CONTENTThis article is linked to Friedman et al papers. To view these articles, visit https://doi.org/10.1111/apt.17113
Bioprosthetic Aortic Valve Thrombosis and Literature Review
Radovanovic, Milan , Nordstrom, Charles W. , Hanna, Richard D.

Mayo Clinic

Journal of Cardiovascular Development and Disease | August 7, 2022 | Volume: 9 | Issue: 8 | Pages: 252

10.3390/jcdd9080252 | PMID 36005416 Get It

An 83-year-old gentleman with a history of 23-mm Hancock-II-bioprosthetic aortic valve (BAV) replacement ten-years prior presented with symptoms of dyspnea and lower extremity edema. During the preceding seven-years, he had been noted to have asymptomatic increased mean transvalvular gradients (MG; 36–50 mmHg) felt to be due to either early bioprosthetic degeneration, pannus formation, or patient–prosthesis mismatch. An echocardiogram at the time of symptom development demonstrated significant flow acceleration through the aortic valve, mild regurgitation, and severely increased MG (48 mmHg) with prolonged acceleration time (AT, 140 msec). A trial of warfarin anticoagulation resulted in dramatic improvement after only 6 weeks with laminar flow through the AV, near-total resolution of regurgitation, and a decrease in MG to 14 mmHg and AT to 114 msec. These findings strongly suggest that BAV thrombosis was the predominant mechanism responsible for the longstanding high MG. Our case highlights that BAV thrombosis should be considered in the differential of elevated gradients regardless of the age of prosthesis, and that a trial of warfarin anticoagulation may be beneficial even if elevated gradients have been present for a prolonged period. Valvular gradients are often abnormal long before a formal diagnosis; however, these may reverse quickly with anticoagulation therapy.
Systematic Functional Analysis of PINK1 and PRKN Coding Variants
Broadway, Benjamin J. , Boneski, Paige K, Bredenberg, Jenny M., Kolicheski, Ana , Hou, Xu , Soto‐Beasley, Alexandra I. , Ross, Owen A. , Springer, Wolfdieter , Fiesel, Fabienne C. , Ross, Owen A , Fiesel, Fabienne C , Springer, Wolfdieter , Hou, Xu , Beasley, Alexandra I

Mayo Clinic

Cells | August 7, 2022 | Volume: 11 | Issue: 15 | Pages: 2426

10.3390/cells11152426 | PMID 35954270 Get It

Loss of either PINK1 or PRKN causes an early onset Parkinson’s disease (PD) phenotype. Functionally, PINK1 and PRKN work together to mediate stress-activated mitochondrial quality control. Upon mitochondrial damage, PINK1, a ubiquitin kinase and PRKN, a ubiquitin ligase, decorate damaged organelles with phosphorylated ubiquitin for sequestration and degradation in lysosomes, a process known as mitophagy. While several genetic mutations are established to result in loss of mitophagy function, many others have not been extensively characterized and are of unknown significance. Here, we analyzed a set of twenty variants, ten in each gene, focusing on understudied variants mostly from the Parkinson’s progressive marker initiative, with sensitive assays to define potential functional deficits. Our results nominate specific rare genetic PINK1 and PRKN variants that cause loss of enzymatic function in line with a potential causative role for PD. Additionally, we identify several variants with intermediate phenotypes and follow up on two of them by gene editing midbrain-derived neuronal precursor cells. Thereof derived isogenic neurons show a stability defect of the rare PINK1 D525N mutation, while the common PINK1 Q115L substitution results in reduced kinase activity. Our strategy to analyze variants with sensitive functional readouts will help aid diagnostics and disease treatment in line with current genomic and therapeutic advances.
A New Clinical Instrument for Estimating the Ambulatory Status after Irradiation for Malignant Spinal Cord Compression
Rades, Dirk , Al-Salool, Ahmed , Staackmann, Christian, Cremers, Florian , Cacicedo, Jon , Lomidze, Darejan, Grošelj, Blaž , Jankarashvili, Natalia , Conde-Moreno, Antonio J. , Ciérvide, R. , Kristiansen, Charlotte , Jankarashvili, Natalia , Ciervide, Raquel , Kristiansen, Charlotte , Schild, Steven E. , Šegedin, Barbara

Mayo Clinic

Cancers | August 7, 2022 | Volume: 14 | Issue: 15 | Pages: 3827

10.3390/cancers14153827 | PMID 35954490 Get It

Estimating post-treatment ambulatory status can improve treatment personalization of patients irradiated for malignant spinal cord compression (MSCC). A new clinical score was developed from data of 283 patients treated with radiotherapy alone in prospective trials. Radiotherapy regimen, age, gender, tumor type, interval from tumor diagnosis to MSCC, number of affected vertebrae, other bone metastases, visceral metastases, time developing motor deficits, ambulatory status, performance score, sensory deficits, and sphincter dysfunction were evaluated. For factors with prognostic relevance in the multivariable logistic regression model after backward stepwise variable selection, scoring points were calculated (post-radiotherapy ambulatory rate in % divided by 10) and added for each patient. Four factors (primary tumor type, sensory deficits, sphincter dysfunction, ambulatory status) were used for the instrument that includes three prognostic groups (17–21, 22–31, and 32–37 points). Post-radiotherapy ambulatory rates were 10%, 65%, and 97%, respectively, and 2-year local control rates were 100%, 75%, and 88%, respectively. Positive predictive values to predict ambulatory and non-ambulatory status were 97% and 90% using the new score, and 98% and 79% using the previous instrument. The new score appeared more precise in predicting non-ambulatory status. Since patients with 32–37 points had high post-radiotherapy ambulatory and local control rates, they may not require surgery.
The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging
Stummer, Walter , Holling, Markus , Vogelbaum, Michael A. , Cox, Ashley , Renfrow, Sara L., Widhalm, Georg , Ezrin, Alan M., DeSena, Salvatore, Sackman, Murray L., Wyse, Joseph W., Widhalm, Georg , Bendok, Bernard R. , Cox, Ashley

Mayo Clinic

Brain Sciences | August 7, 2022 | Volume: 12 | Issue: 8 | Pages: 1044

10.3390/brainsci12081044 | PMID 36009108 Get It

Background: 5-aminolevulinic acid (5-ALA; GleolanTM, NX Development Corps., Lexington, USA) is approved for fluorescence-guided resections of suspected malignant gliomas. Experience has demonstrated that meningiomas also show fluorescence, which may be a useful surgical adjunct. We present an innovative design for a multi-center, prospective study to determine the clinical safety and potential benefit of fluorescence-guided resection of meningiomas with utmost bias reduction. Methods: All patients with suspected meningioma (all grades) receive GleolanTM 20 mg/kg 2–4 h prior to surgery supported by fluorescence excitation from a blue light source (Blue400, Zeiss Meditech, Oberkochen, Germany; FL400, Leica Microsystems, Heerbrugg, Switzerland). Surgeons are asked whether a residual tumor can be observed to fluoresce under blue light (BL) after the tumor is no longer recognizable using conventional illumination at the end of surgery. In addition, when faced with tissues of uncertain tissue type (so-called “indeterminate” tissue), this study records how often surgeons make a correct decision based on fluorescence and how this influences surgical strategy. The primary endpoint is the percentage of patients in whom one of these two benefits are observed. Other endpoints include the diagnostic accuracy of fluorescence compared to white light (WL) versus correlative histology. For bias reduction, pertinent data are derived from surgical videos reviewed by independent reviewers blinded to surgeons’ assessments of tissue type and fluorescence status. Data will be included from approximately 100 study participants completing the study at approximately 15 centers in the United States, Germany, and Austria. Results: As of May 2022, 88 patients have completed the study. No adverse safety signal has been detected. Conclusions: Preliminary data confirm the feasibility of our study design. Accrual is targeted for completion in the third quarter of 2022.
Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review
Ayala, Ivan N. , Aziz, Syed N, Argudo, Jennifer M, Yépez, Mario , Camacho, Mikaela , Ojeda, Diego , Aguirre, Alex S. , Oña, Sebastian, Andrade, Andres F , Vasudhar, Ananya, Moncayo, Juan A , Hassen, Gashaw , Ortíz, Juan Fernando , Tambo, Willians , Ayala, Iván Nicolas

Mayo Clinic

Brain Sciences | August 7, 2022 | Volume: 12 | Issue: 8 | Pages: 1040

10.3390/brainsci12081040 | PMID 36009103 Get It

Ataxia is a constellation of symptoms that involves a lack of coordination, imbalance, and difficulty walking. Hereditary ataxia occurs when a person is born with defective genes, and this degenerative disorder may progress for several years. There is no effective cure for ataxia, so we need to search for new treatments. Recently, interest in riluzole in the treatment of ataxia has emerged. We conducted this systematic review to analyze the safety and efficacy of riluzole for treating hereditary ataxia in recent clinical trials. We conducted a systematic review using PubMed and Google Scholar as databases in search of this relationship. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocols to conduct this study. For inclusion criteria, we included full-text clinical trials on humans written in English and found three clinical trials. We excluded case reports, literature reviews, systematic reviews, and meta-analyses for this analysis. We aimed to evaluate the Scale for the Assessment and Rating of Ataxia (SARA) score, the International Cooperative Ataxia Rating Scale (ICARS) score, and the safety of the medication. Two out of the three clinical trials showed statistically significant clinical improvement in the ICARS and SARA scores, while the other trial did not show improvement in the clinical or radiological outcomes. The drug was safe in all clinical trials. Overall, the results of this analysis of riluzole for the treatment of hereditary ataxia are encouraging. Further clinical trials are needed to investigate the efficacy of riluzole on hereditary ataxia.
Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
D’Souza, Ryan S. , Her, Yeng F , Jin, Max Y. , Morsi, Mahmoud , D'Souza, Ryan S , Abd-Elsayed, Alaa A

Mayo Clinic

Biomedicines | August 7, 2022 | Volume: 10 | Issue: 8 | Pages: 1909

10.3390/biomedicines10081909 | PMID 36009456 Get It

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted.
Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Walden, Daniel, Eslinger, Cody , Bekaii‐Saab, Tanios , Achilonu, Conrad Chibunna , Bekaii-Saab, Tanios S , Achilonu, Conrad C , Walden, Daniel

Mayo Clinic

Therapeutic Advances in Gastroenterology | August 6, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221115317 | PMID 35967919 Get It

Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently, advancements in genetic sequencing have opened new avenues of targeted treatment. In cholangiocarcinoma, FGFR2 alterations have been shown to be present in roughly 10–15% of intrahepatic cholangiocarcinoma. Pemigatinib, a FGFR1–4 inhibitor, has been shown to significantly extend survival in the second-line setting to over 20 months in patients who harbor FGFR2 fusions. Here, we outline the development and future direction of pemigatinib and other FGFR2 inhibitors in the field of advanced biliary tract cancers.
Consensus on an implicit bias and health disparities curriculum in neonatal medicine: a Delphi study
Mavis, Stephanie C. , Caruso, Catherine G. , Carr, Cara E, Dyess, Nicolle Fernández , French, Heather , Dadiz, Rita , Vásquez, Margarita , Johnston, Lindsay , Gillam-Krakauer, Maria , Chess, Patricia R., Izatt, Susan , Carbajal, Melissa M. , Bonachea, Elizabeth , Mavis, Stephanie , Payne, Allison H. , Gray, Megan M

Mayo Clinic

No container title available | August 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1915181/v1 Get It

Abstract OBJECTIVEDespite longstanding and recurrent calls for effective implicit bias (IB) education in health professions education as one mechanism to reduce ongoing racism and health disparities, evidence-based IB curricula for neonatal-perinatal medicine (NPM) are limited. We aim to determine the key IB curricular elements for teaching NPM fellows, advanced practice providers, and attending physicians. STUDY DESIGNA modified Delphi study was performed with content experts in IB and health disparities who had educational relationships to those working and training in the neonatal intensive care unit. RESULTThree Delphi rounds were conducted. Experts reached consensus on a variety of items for inclusion in an IB curriculum, including educational goals, learning objectives, teaching strategies, and educator principles.CONCLUSIONEssential IB curricular components for the field of neonatal medicine were defined using rigorous consensus building methodology.
Bias Reduction in Representation of Histopathology Images Using Deep Feature Selection
Bidgoli, Azam Asilian , Rahnamayan, Shahryar , Dehkharghanian, Taher , Grami, Ali, Tizhoosh, Hamid R.

Mayo Clinic

No container title available | August 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1882716/v1 Get It

Abstract Appearing traces of bias in deep networks is a serious issue that can play a significant role in ethics and generalization. Recent studies report that the deep features extracted from the histopathology images of The Cancer Genome Atlas (TCGA), the largest publicly available archive of 11,000 patients covering 25 organs and 32 cancer subtypes, are surprisingly able to accurately classify the whole slide images (WSIs) based on their acquisition site. This is clear evidence that the utilized Deep Neural Networks (DNNs) unexpectedly detect the specific patterns of the source site rather than histomorphologic patterns, biased behaviour resulting in degraded generalization. This observation motivated us to propose a method to alleviate the destructive impact of hospital bias through a novel feature selection process. To this effect, we have proposed an evolutionary strategy select a small set of optimal features to not only accurately represent the histological patterns of tissue samples but also to eliminate the features leading to internal bias toward the institution. The performance of the proposed method has been assessed using the features extracted from TCGA images made available by NIH (National Institute of Health). The selected features extracted by a state-of-the-art network trained on TCGA images (i.e., the KimiaNet), considerably decreased the institutional bias. The proposed scheme is not limited to DNNs and/or specific types of biases; it can be employed to reduce various kinds of bias in a much more comprehensive range of data-driven feature extraction models. The conducted experiments, the external validation in specific, clearly demonstrate that the bias cannot be fully controlled just during training a model. Therefore, a feature selection for downstream tasks plays a crucial role in significantly reducing the bias.